home / stock / atai / atai news


ATAI News and Press, ATAI Life Sciences N.V. From 09/15/23

Stock Information

Company Name: ATAI Life Sciences N.V.
Stock Symbol: ATAI
Market: NASDAQ
Website: atai.life

Menu

ATAI ATAI Quote ATAI Short ATAI News ATAI Articles ATAI Message Board
Get ATAI Alerts

News, Short Squeeze, Breakout and More Instantly...

ATAI - Exploring Effects of Simultaneous Opioid, Psychedelic Use for Chronic Pain

Recent research investigating the interaction between psychedelics and opioids has found that using the two together to treat chronic pain may not be a good idea. Opioids have been the go-to treatment for pain disorders for a long time, but they have lost popularity over the past decade, especi...

ATAI - atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Cantor Fitzgerald Global Healthcare Conferenc...

ATAI - California House Passes Psychedelics Bill, Resends to Senate

California Assembly members have approved a psychedelic legalization measure passed by the Senate before sending it back to the Senate for discussions on recent amendments. The bill could potentially land on Governor Gavin Newsom’s desk once it advances through the Senate, putting Califo...

ATAI - Timothy Leary Expounds on Five Stages Psychedelic Users Could Experience During a Trip

Even though psychedelics have been illegal since the 1970s, psychedelic use among people has surged in recent years , partly due to claims of psychedelics’ therapeutic properties and the fact that younger generations are increasingly moving away from alcohol and tobacco. For people look...

ATAI - Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies

2023-09-01 19:02:09 ET Summary Atai Life Sciences is advancing RL-007 for the treatment of cognitive impairment associated with schizophrenia, with top-line results expected in the 2nd half of 2024. The company is also working on advancing COMP360 for treatment-resistant depressio...

ATAI - Psilocybin in depression: study shows lasting benefit

2023-08-31 12:35:49 ET More on psychedelic drugmakers Compass Pathways: Debt Deal Secured, Cash Runway Extended COMPASS Pathways plc ( CMPS ) Q2 2023 Earnings Call Transcript Mind Medicine Inc. ( MNMD ) Q2 2023 Earnings Call Transcript Psychedelic Sto...

ATAI - More Employers Including Psychedelic Therapy in Health Benefits Packages

Psychedelics have the potential to revolutionize psychiatry by significantly improving treatment outcomes and safety while minimizing side effects. A plethora of studies have revealed that hallucinogenic compounds such as psilocybin can be especially effective when combined with talk therapy, p...

ATAI - Psychedelics Could Transform How People Age, Die

Psychedelics are poised to transform mental health and the psychiatry industry in major ways. A recent surge of psychedelic-related research and clinical trials has revealed that the federally controlled drug may have prolific mental health benefits, especially against conditions that don...

ATAI - Experts Call for Psychedelics to Be Investigated as Cancer Distress Treatments

A panel of expert authors is calling on authorities to facilitate the study of psychedelic compounds as cancer distress treatments . In a paper published in the “International Journal of Gynecological Cancer ,” the authors noted that women with late-stage gynecologic tumors often ...

ATAI - Psychedelic therapy should be done in conjunction with psychotherapy - group

2023-08-22 12:50:11 ET More on psychedelic drug companies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down Psychedelic Stocks: Don't Bet On Just 1 Company Seelos:...

Previous 10 Next 10